PosterHIVViral Hepatitis and Liver DiseaseDolutegravir (DTG) Plasma Concentrations Under Different Combinations Regimens for ART- Pre-Treated Adults Living With HIVView Poster
PosterHIVViral Hepatitis and Liver DiseaseTargeting Nuclear Receptors to Prevent Cobicistat HepatotoxicityView Poster
PosterHIVViral Hepatitis and Liver DiseasePopulation Pharmacokinetic Modelling of Atazanavir in Plasma and Hair of HIV-Infected WomenView Poster
PosterHIVViral Hepatitis and Liver DiseaseTacrolimus and Sirolimus Doses in an HIV-Infected, Kidney-Recipient, Patient Requiring a Cobicistat-Based Antiretroviral RegimenView Poster
PosterHIVViral Hepatitis and Liver DiseaseThe Pharmacokinetics (PK) of DOVATO (50 mg Dolutegravir (DTG)/ 300 mg Lamivudine (3TC)) Fixed-Dose Combination in HIV-Infected PatientsView Poster
PosterHIVViral Hepatitis and Liver DiseasePharmacokinetics, Safety, and Tolerability of Dolutegravir + Rilpivirine (JULUCA) in Healthy Japanese AdultsView Poster
PosterHIVViral Hepatitis and Liver DiseaseIn Utero Exposure to Antiretroviral Drugs and Pregnancy Outcomes: A Secondary Analysis of the ANRS Pharmacovigilance Database From the ANRS-Sponsored HIV Research StudiesView Poster
PosterHIVViral Hepatitis and Liver DiseaseImpact of the Hepatitis B Virus (HBV) Capsid Inhibitor, AB-506, on the Single Dose Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)View Poster
PosterHIVViral Hepatitis and Liver DiseaseSystematic Review and Meta-Analysis of Adverse Perinatal Outcomes Associated With Prenatal Exposure to Protease Inhibitor Combination in Pregnant Women With HIV InfectionView Poster
PosterHIVViral Hepatitis and Liver DiseaseEvaluation of Relationships Between AB-506 Related ALT Elevations and AB-506 Pharmacokinetics (PK), Metabolite Concentrations and Plasma Bile AcidsView Poster
